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Abstract
Invasive candidiasis ranges from 5 to 10 cases per 1,000 ICU admissions and represents 5% to 10% of all ICU-acquired
infections, with an overall mortality comparable to that of severe sepsis/septic shock. A large majority of them are
due to Candida albicans, but the proportion of strains with decreased sensitivity or resistance to fluconazole is
increasingly reported. A high proportion of ICU patients become colonized, but only 5% to 30% of them develop an
invasive infection. Progressive colonization and major abdominal surgery are common risk factors, but invasive
candidiasis is difficult to predict and early diagnosis remains a major challenge. Indeed, blood cultures are positive in
a minority of cases and often late in the course of infection. New nonculture-based laboratory techniques may
contribute to early diagnosis and management of invasive candidiasis. Both serologic (mannan, antimannan, and
betaglucan) and molecular (Candida-specific PCR in blood and serum) have been applied as serial screening
procedures in high-risk patients. However, although reasonably sensitive and specific, these techniques are largely
investigational and their clinical usefulness remains to be established. Identification of patients susceptible to benefit
from empirical antifungal treatment remains challenging, but it is mandatory to avoid antifungal overuse in critically
ill patients. Growing evidence suggests that monitoring the dynamic of Candida colonization in surgical patients and
prediction rules based on combined risk factors may be used to identify ICU patients at high risk of invasive
candidiasis susceptible to benefit from prophylaxis or preemptive antifungal treatment.
Epidemiology of invasive candidiasis
Whereas in the past, opportunistic mycoses, such as Can-
dida and Aspergillus, typically occurred in immunocom-
promised hosts, these complications are increasingly
observed in nonimmunocompromised surgical and criti-
cally ill adult patients [1,2]. These trends were confirmed
by a recent large international prevalence survey in ICUs,
which reported infections due to Candida and Aspergillus
in 17% and 1.4% patients, respectively [3].
Incidence of candidemia
A large epidemiological survey in the United States
reported a threefold increase of fungal sepsis during the
period 1979-2000, and candidemia was reported to be
the third most common cause of nosocomial blood-
stream infection (BSI) in critically ill adult patients,
representing 11% of all BSI [4,5]. The incidence of can-
didemia in U.S. hospitals during 2000-2005 increased
from 3.65 to 5.56 episodes per 100,000 population [6].
Incidences are usually tenfold higher in the ICUs than
in other wards: 3 to 15 episodes per 10,000 ICU
patients-days or 2 to 10 cases per 1,000 ICU admissions
are reported, with highest rates among surgical patients
[1,7].
Data from Europe have shown that the incidence of
candidemia may be lower, with proportions ranging
from 2-3% of bloodstream isolates [2,8]. A recent
national surveillance, including 2,820 cases of fungemia
in Denmark during the period 2004-2009, reported an
increasing incidence from 7.7 to 8.6 per 100,000 [9].
Despite important regional differences, these data show
that Candida is among the top ten bloodstream patho-
gens and suggest an increasing incidence of candidemia
during the past 5 to 10 years.
Distribution of species
A large geographical variation of the proportions of the
different Candida species has been reported (Table 1)
[2,7-16]. In North and South America, non-albicans
Candida species account for more than half of the
bloodstream isolates: C. glabrata and C. parapsilosis are
the predominant non-albicans species, respectively.
Whereas in Europe, C. albicans remains the most
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frequent species, epidemiological trends suggest that
non-albicans Candida species, in particular C. glabrata,
are emerging. In addition to differences in the fungal
ecology of the different continents, the large use of
azoles antifungal agents may have contributed to this
progressive shift of the epidemiology of candidemia.
Antifungal susceptibility
Rates of reduced antifungal susceptibility or resistance
ranging from < 5% to > 30% have been reported. The
antifungal susceptibility of 2,085 Candida isolates to
echinocandins (anidulafungin, micafungin) to new azoles
(posaconazole, voriconazole) and to fluconazole were
tested in the SENTRY survey according to the new Clin-
ical and Laboratory Standard Institute (CLSI) break-
points [10]. In C. albicans, no resistance to the five
antifungals was observed. In contrast, resistance rates
for C. glabrata were reported to be: fluconazole 5.6%,
posaconazole 3.7%, voriconazole 3.5%, anidulafungin
2.4%, and micafungin 1.9%, respectively. C. parapsilosis
was found to be resistant to fluconazole in 5% of the
isolates. C. tropicalis was resistant to fluconazole in
3.2% of isolates, to posaconazole in 0.9%, and to vorico-
nazole in 2.9%. Finally, C. krusei was resistant in 2.5% of
cases to voriconazole, whereas no resistance to posaco-
nazole and to the two echinocandins was found. In
Denmark, the proportion of fully susceptible species
decreased from 79.7% to 68.9% [9]. Leroy et al. reported
a decreased susceptibility to fluconazole in 17% of iso-
lates from 180 French ICUs [7].
Selective pressure of antifungals on species distribution
Preexposure to antifungals, such as prophylaxis, in particu-
lar with azoles, and to a lesser extent with echinocandins,
has been associated with the occurrence of breakthrough
infections with resistant Candida species. Whereas
C. glabrata and C. krusei have been classically observed in
these settings, other resistant non-albicans Candida spe-
cies are being increasingly observed [17,18]. This was
recently confirmed in a large prospective multicenter
study conducted by the French Mycosis Study Group in
2,441 candidemic patients reporting that preexposure to
fluconazole (159 episodes) or caspofungin (61 episodes)
was associated with a higher proportion of less drug-
susceptible C. glabrata or C. krusei (odds ratio (OR), 2.45;
95% confidence interval (CI), 1.39-4.31) and C. parapsilo-
sis, C. glabrata, or C. krusei (OR, 4.79; 95% CI, 2.47-9.28),
respectively [19]. These observations are not only of epide-
miological interest, but the decreased in vitro antifungal
susceptibility has been showed to be associated with
increased morbidity and mortality in both immunocom-
promised and critically ill patients [7,20]. Monitoring of
Table 1 Distribution of Candida species in epidemiological surveys during the past decades
Author Period of
observation
Study Region No. of
strains
Candida
albicans
Candida
tropicalis
Candida
parapsilosis
Candida
glabrata
Candida
krusei
Other
Candida
Pfaller et al. [10] 2008-2009 SENTRY Worldwide 2’085 48% 11% 17% 18% 2% 4%
Europe 750 55% 7% 14% 16% 3% 4%
North
America
936 43% 11% 17% 24% 2% 4%
Latin
America
348 44% 17% 26% 5% 1% 5%
Asia 51 57% 12% 14% 14% 2% 2%
Marra et al. [11] 2007-2010 SCOPE Brazil 137 34% 15% 24% 10% 2% 17%
Arendrup et al.
[9]
2004-2007 Denmark 2901 57% 5% 4% 21% 4% 9%
Horn et al. [12] 2004-2008 PATH North
America
2019 46% 8% 16% 26% 3% 1%
Leroy et al. [7] 2005-2006 AmarCand France
ICU
305 57% 5% 8% 17% 5% 8%
Talarmin et al.
[13]
2004 France
West
193 55% 5% 13% 19% 4% 4%
Bougnoux et al.
[14]
2001-2002 Paris
ICU
57 54% 9% 14% 17% 4% 2%
Marchetti et al.
[2]
1991-2000 FUNGINOS Switzerland 1137 64% 9% 1% 15% 2% 9%
Sandven et al.
[15]
1991-2003 Norway
Nationwide
1393 70% 7% 6% 13% 1% 3%
Pfaller et al. [16] 1997-2005 ARTEMIS Mondial ** 55’229 71% 5% 5% 10% 2% 7%
Tortorano et al.
[8]
1997-1999 ECMM Europe 2089 52% 7% 13% 13% 2% 13%
Eggimann et al. Annals of Intensive Care 2011, 1:37
http://www.annalsofintensivecare.com/content/1/1/37
Page 2 of 10
resistance plays an important role for updating treatment
recommendations designed to improve patients’ outcome.
Impact of invasive candidiasis
Candidemia typically occurs in colonized patients who
accumulate other risk factors, such as major surgery,
intravascular catheters, and antibacterial exposure, dur-
ing a prolonged ICU stay [1,21]. It occurs at a median
of 22 days after hospital admission compared with 13
days for Escherichia coli and 16 days for Staphylococcus
aureus bacteremias according to the U.S. population-
based SCOPE study [5]. It occurred 14 (interquartile
range, (IQR), 5-25) days and 19 (± 3) days after ICU
admission, in a survey of a university hospital from Paris
and in the EPIC II study, respectively [14,22].
Candidemia is associated with significant morbidity,
which is reflected by a long ICU and hospital stay, ranging
between one and several weeks [7,14]. The overall mortal-
ity in patients with invasive Candida infections is high:
42.6% in the EPIC II study [22]; 35.2% at 12 weeks in the
PATH study [12]; 37.9% in the ECMM study [8]; and
53.4% in non-ICU vs. 85.9% in ICU patients in the Brazi-
lian SCOPE study [11]. In the PATH study, the highest
mortality has been reported in C. krusei infections (52.9%)
and the lowest in C. parapsilosis infections (23.7%),
whereas intermediate rates were reported for C. albicans
(35.6%), C. glabrata (38.1%), and C. tropicalis (41.1%) [12].
Similar differences were found in the ECMM and the
French surveys [7,8]. Significant differences in mortality in
age groups also were reported: 16.8% in patients 0-19
years of age, 31.3% in 19-65 years of age, and 52.7% in >
65 years of age [12]. Mortality higher than 80% was
reported in candidemic patients with septic shock [23].
The mortality attributable to candidemia ranged from 5-
49% according to the different types of studies (retrospec-
tive vs. prospective), patients (ICU vs. non-ICU, age), and
healthcare settings [8,24,25].
A substantial difference in mortality between patients
who receive appropriate antifungal therapy (< 5%) and
those without appropriate therapy (25-40%) was observed
in patients with septic shock [23]. Therapy of candidemia
delayed beyond 12 h after sampling of blood has been
associated with an increase of in-hospital mortality from
< 20% to 40% [26,27]. Because incubation accounts for
the majority of the time elapsed between sampling of
blood cultures and starting antifungal therapy, these data
highlight the need for new noninvasive tools for antici-
pating diagnosis of invasive candidiasis in high-risk
patients, which may play a key role for early and targeted
empirical or preemptive treatment strategies [28-30].
Pathogenesis of invasive candidiasis
During past decades, many risk factors associated with
the development of invasive candidiasis have been
identified (Table 2) [21,31-33]. Among them, Candida
colonization plays a key role in the pathogenesis of inva-
sive candidiasis. Selective pressure trough antibacterial
therapy alters the microbiota, resulting in overgrowth of
Candida species on skin and mucosal surfaces [1]. Inva-
sive procedures that disrupt natural skin or mucosal
barriers, such as intravascular catheters, gastrointestinal
tract surgery, and chemotherapy-associated mucositis, as
well as decreased host defenses, in particular neutrope-
nia, facilitate local invasion and further candidemia
(Figure 1).
Host defenses against colonization of mucous mem-
branes by Candida and invasion of tissues and/or dissemi-
nation via the bloodstream rely on distinct immunological
mechanisms [34]. Recognition of fungi-associated molecu-
lar patterns involves several classes of pattern-recognition
receptors. Toll-like receptors (TLRs) 2 and 4 recognize
fungal cell-wall structures (mannans) and induce the pro-
duction of proinflammatory cytokines [35]. Beta-1,3 glu-
cans are sensed by dectin-1, a member of the C-type lectin
family of receptors. Activation of the signal transduction
pathways downstream of these receptors ultimately lead to
the production of a complex array of mediators, including
proinflammatory cytokines (such as TNF and IL-1)
involved in adaptive immune response [36]. CD4+ T cells
have been shown to play a critical role in host defenses
against Candida infections. The interferon (IFN)-g-
mediated Th1 response stimulates the production of
Table 2 Risk factors associated with the development of
invasive candidiasis
Colonization of several body sites
Broad-spectrum antibiotics
Immunosuppression
Neutropenia
Burns (> 50%)
Disruption of physiological barriers in the digestive tract
Major abdominal surgery
Surgery of the urinary tract in presence of candiduria
Major trauma (ISS > 20)
Parenteral nutrition
Hemodialysis
APACHE score II > 20
Central venous catheter
Candiduria > 105 cfu/ml
Young and old ages
Diabetes
Renal failure
Recent surgery
Urinary catheter
Vascular catheters
Prolonged ICU stay (> 7 days)
Multiple transfusions
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specific anti-Candida immunoglobulins, whose role for
prevention and clearance of infection remains to be eluci-
dated [37]. These recent findings open new perspectives
for identifying subgroups of patients at higher risk of
developing invasive candidiasis and who may benefit from
more specifically targeted preventive or preemptive anti-
fungal strategies and/or of immunomodulating approaches
[36].
Diagnosis of candidiasis in critically ill patients
Only 5-15% of patients are colonized by Candida spp. at
ICU admission, but this proportion progressively
increases with time to 50-80% as a result of prolonged
exposure to many risk factors, such as major surgery,
parenteral nutrition, dialysis, and antibiotics [33,38-40].
However, only 5-30% of colonized patients will develop
invasive candidiasis, which is usually a late-onset ICU
acquired infection [7,14]. As the clinical differentiation
between colonized and infected critically ill patients
remains difficult to assess, the utility and cost-effective-
ness of colonization surveillance cultures remain unclear
[41-43].
Two main types of Candida infections predominate.
Candidemia occurs generally after several days or weeks
of ICU stay, whereas Candida peritonitis more closely
follows a complicated abdominal surgery. Conventional
blood cultures, as well as cultures of other sterile body
sites, albeit late and insensitive, remain the key diagnostic
tools to identify Candida to the species level, and allow
to test the activity of various antifungal agents.
Cultures from sites other than blood or normally sterile
body fluids are nonspecific and reflect colonization in the
majority of cases. Blood cultures become positive in a
minority of patients with deep-seated candidiasis and
often only late in the course of infection [7,14,22]. Con-
ventional identification of Candida to the species level
usually requires 1 to 3 days after detection of fungal
growth in blood cultures. The recent development of new
laboratory techniques (fluorescent in situ hybridization
[FISH], and matrix-assisted laser desorption ionization
time of flight mass-spectrometry [MALDITOF-MS]), sig-
nificantly help to reduce the delay to species level identifi-
cation, and thus allow an earlier choice of appropriate
antifungal therapy [44].
Invasive candidiasis other than candidemia is difficult to
diagnose. Clinical signs suggestive of invasive candidiasis
did not differ from those of other nosocomial infections.
More specific manifestations, such as retinal emboli (cot-
ton whole) or hepatosplenic lesions are rare or only
observed in cancer patients after neutrophils recovery
[45,46]. Tissue sampling often requires invasive proce-
dures at high risk of complications and has a low diagnos-
tic yield, especially in patients who have received empirical
therapy.
Nonculture-based methods
The delay between ICU admission and the occurrence
of deep-seated Candida infections allows both to iden-
tify patients at increased risk and to attempt to detect
early onset of infections. Several biomarkers are
Figure 1 Pathophysiology of invasive candidiasis.
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currently tested with this strategy, either based on anti-
gen-antibody detection or on fungal DNA detection in
serum or blood.
Commercially available antigen-based test target a
Candida specific cell-wall component, mannan, or a non-
specific fungal element, beta-D-glucan. Both have a mod-
erate sensitivity (60% for mannan, 83% when combined
to anti-mannan antibodies, 65-80% for beta-D-glucan)
and are intended to be used as a screening strategy two
to three times per week. Mostly tested in oncohematol-
ogy patients, their value in an ICU population is still
insufficiently documented [47,48].
The second noncultural approach relies in detecting the
presence of Candida DNA in the blood of at-risk patients.
The major hurdle to this technique is the lack of commer-
cial easy-to-use methods and the relative low sensitivity of
this approach, due to several factors (low quantity of
Candida cells in the blood, inhibitors due to blood cells).
An additional difficulty is the “gold standard” generally
used in evaluations, blood cultures, which itself lacks sen-
sitivity. Available comparative studies in ICU patients are
limited, showing a sensitivity equal to/or slightly lower
than blood cultures (75-100% compared with blood cul-
tures) [49,50].
Clinical prediction of invasive candidiasis in critically ill
patients
Despite continuous progress and developments in this
field, the absence of laboratory-based method currently
available at the bedside has imposed pragmatic clinical
approaches based on the appreciation of the dynamics
of colonization and/or of the combination of less speci-
fic risk factors [51].
Colonization-based assessment of the risk of invasive
candidiasis
Documentation of increasing amounts of Candida spp. in
semiquantitative cultures from multiple sites has been
found to predict the subsequent development of invasive
candidiasis [21,52,53]. It has been suggested that the pre-
sence of Candida spp. in more than two body sites may
justify the start of antifungal therapy [54,55]. However,
critically ill patients are being colonized progressively
during their ICU stay. The accuracy of a single-point
assessment is low and such rule may be responsible for
overuse of antifungals [56]. As initially proposed by Pittet
et al. and confirmed by other investigators, a periodic
evaluation of the dynamics of colonization in surgical
patients at risk may predict more accurately the develop-
ment of an invasive candidiasis [21,57-60].
In a prospective cohort study of surgical critically-ill
patients, Pittet et al. assessed the degree of colonization
by measuring daily the colonization index defined as the
ratio of the number of distinct body sites colonized with
genotypically identical strains of Candida over the total
number of sites tested [21]. Eleven of 29 heavily colo-
nized patients developed invasive candidiasis. The sever-
ity of the underlying conditions and the degree of
colonization independently predicted the occurrence of
invasive candidiasis. The average Candida colonization
index was 0.47 for colonized vs. 0.7 for infected patients,
respectively (p < 0.01). Furthermore, a threshold ≥0.5
identified all infected patients at an average of 6 days
before the diagnosis of invasive candidiasis.
The usefulness of the colonization index has never been
demonstrated in a large prospective clinical trial, but its
potential clinical value has been suggested in at least nine
studies. Dubau et al. reported that an invasive candidiasis
developed in only 1 of 35 surgical patients in whom
empirical antifungals were prescribed when the index
reached 0.5 and that it decreased rapidly in the 34 other
patients [61]. Garbino et al. prospectively observed a
decrease of the index in a group of critically ill patients
receiving antifungal prophylaxis [42]. In contrast, it
increased with time in those who received a placebo. Dif-
ferences reached statistical significance between the two
groups after 7 days. Chabasse et al. found a correlation
between quantitative urine cultures above 104 cfu/mL and
a colonization index ≥0.5 [62]. Charles et al. reported sig-
nificantly higher values in medical patients (0.74 ± 0.31)
compared with surgical patients 0.45 ± 0.4 (p = 0.01) [57].
The index increased significantly by 0.1 during the ICU
stay (p = 0.016) and the threshold of 0.5 was reached in 36
(39.1%) of 92 nonsurgical ICU patients staying > 7 days; 6
of them developed invasive candidiasis [63]. Hematological
malignancy, duration of exposure to broad-spectrum anti-
biotics, fungal colonization at entry, and candiduria pre-
dicted an increase in the colonization index. In contrast,
the duration of exposure to antifungals was significantly
associated with its decrease. Compared with an historical
cohort of 455 controls, the rate of invasive candidiasis
decreased from 7% to 3.6% in a cohort of 478 surgical ICU
patients who received preemptive antifungal treatment if
the corrected colonization index was > 0.4 [64]. This strat-
egy avoided the development of ICU-acquired invasive
candidiasis. Normand et al. reported a significant reduc-
tion of the colonization index in a cohort of 98 patients
mechanically ventilated > 48 hours randomized to receive
prophylaxis by oral nystatin [65]. Agvald-Öhman et al.
showed that increases of colonization index after major
abdominal surgery were significantly correlated with the
development of an IC [59]. Senn et al. reported a signifi-
cant decrease of the colonization index in critically ill
patients empirically treated with caspofungin after recur-
rent gastrointestinal perforation/anastomotic leakage or
acute necrotizing pancreatitis [60].
Although these observations strongly suggests that the
colonization index may be used to identify among
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colonized critically ill patients those who are susceptible
to benefit from early initiation of antifungal therapy, this
strategy is work-intensive, expensive, and difficult to
implement on a routine basis at the bedside [66]. Its
cost-effectiveness and usefulness for the management of
critically ill patients remains to be proved in prospective
comparative clinical trials [30]. In addition, limited data
are available for nonsurgical patients.
Risk of invasive candidiasis assessed by scores or
predictive rules
Scoring systems or predictive rules that combine clinical
risk factors and information for Candida colonization
have been recently proposed [67-69]. A risk-based
“Candida score” has been developed by Leon et al. in a
prospective cohort of 1,699 ICU patients staying more
than 7 days [68]. Surgery (OR, 2.71; 95% CI, 1.45-5.06),
multifocal colonization (OR, 3.04; 95% CI, 1.45-6.39), total
parenteral nutrition (OR, 2.48; 95% CI, 1.16-5.31), and
severe sepsis (OR, 7.68; 95% CI, 4.14-14.22) significantly
predicted invasive candidiasis. By attributing one point of
each risk factor, the score for a cutoff value of 2.5 had a
sensitivity and specificity of 81% and 74%, respectively.
The usefulness of this risk-factor based “Candida score”
has been demonstrated further to rule out invasive candi-
diasis [70]. In a multicenter cohort of 1,007 patients stay-
ing for more than 7 days, only 13 of 565 (2.3%) patients
with a score < 3 points developed a candidiasis, corre-
sponding to a negative predictive value of 98%. In this ser-
ies, a linear progression of the risk of invasive candidiasis
and higher score was further observed. The accuracy of a
colonization index ≥0.5 (relative risk, 5.98, 95% CI, 3.28-
10.92) was lower than a Candida score ≥3 (relative risk,
5.98; 95% CI, 3.28-10.92).
Using a similar conceptual approach, Paphitou et al.
identified retrospectively individual risk factors for the
Table 3 Criteria used for antifungal prophylaxis in adult critically ill patients
Study Criteria used for prophylaxis Antifungal used for
prophylaxis
Invasive
candidiasis
Commentary
Positive prophylactic studies
*Slotman et
al.
1987 [77]
Abdominal surgery
+ ≥ 3 risk factors
Ketoconazole 200 mg/d PO
Placebo
0/27 (0%)
5/30 (17%)†
Costs: $4,800 vs. $10,000†
LOS: 6.0 vs. 12.5 days†
*Savino et al.
1992 [78]
Surgical patients
+ hypermetabolism
Nystatin/norfloxacin PO
Placebo
6/25 (24%)
13/21 (62%)‡
NI per patient:
0.9 vs. 2.0†
Desai et al.
1992 [79]
Severely burned patients Nystatin/polymyxin SDD
No prophylaxis
34/1042 (3.3%)
0/1439 (0%)†
Superficial infections:
59 (21%) vs. 22 (10%)†
Eggimann et
al.
1999 [39] *
Abdominal surgery
+ tertiary peritonitis
Fluconazole 400 mg/d IV
Placebo
1/23 (9%)
7/20 (35%)‡
Candida peritonitis
1 (4%) vs. 7 (35%)†
Pelz et al.
2001 [43] *
Surgical patients
+ LOS > 3 days
Fluconazole 400 mg/d PO
Placebo
11/130 (8%)
20/130 (15%)†
> 75% colonized at randomization
Garbino et al.
2002 [42] *
Mechanically ventilated > 96 h Fluconazole 100 mg PO +
SDD
Placebo + SDD
4/103 (4%)
10/101 (10%)‡
Candidemia: 9 vs. 1
(RR 0.1; CI 0.02-0.74)†
Jacobs et al.
2003 [80] *
ICU
+ septic shock
Fluconazole 200 mg IV/d
Placebo
0/32 (0%)
1/39 (3%)‡
Mortality significantly reduced in
peritonitis
He et al.
2003 [81]
Severe acute pancreatitis Fluconazole 100 mg IV/d
Placebo
2/22 (9%)†
7/23 (30%)†
Mortality 2/2 (100%)
Mortality 3/7 (43%)
Negative prophylactic studies
Savino et al.
1994 [78]
Surgical patients
+ LOS > 2 days
Nystatin 2 × 106 4 ×/d PO
Ketoconazole 200 mg/d PO
Clotrimazole 10 mg 3 ×/d PO
No prophylaxis
5/75 (7%)
1/65 (2%)‡
1/80 (1%)‡
2/72 (3%)‡
Ables et al.
2000 [82]*
Surgical patients
+ LOS > 2 days + other risk factors
Fluconazole 3 mg/kg 3 ×/w
Placebo
8/60 (13%)
11/59 (19%)‡
Sandven et
al.
2002 [40]*
Surgery for peritonitis Fluconazole 400 mg/d IV
Placebo
-
-
Mortality rates NS
4/53 (8%) vs. 8/56 (14%)
Schuster et
al.
2008 [83]*
ICU ≥ 4 d
+ Fever > 4 d under broad-spectrum
antibiotics
+ APACHE II ≥ 16
Fluconazole 400 mg/d IV
Placebo
6/122 (5%)
11/127 (9%)‡
*Prospective randomized double-blind
†p < 0.05
‡Not significant
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development of invasive candidiasis in a cohort of 327 sur-
gical ICU patients to build a predictive rule [71]. The rate
of invasive candidiasis was 17% for patients staying more
than 3 days in ICU, with the combination of diabetes mel-
litus, dialysis, total parenteral nutrition, and exposure to
broad-spectrum antibiotics compared with 5% for those
lacking these characteristics (p < 0.01). Fifty-two percent
of patients met this rule, which captured 78% of those
who developed invasive candidiasis. For patients staying 4
days or more, Ostrosky-Zeichner et al. refined this preli-
minary clinical prediction rule in a large multicenter retro-
spective study [72]. Any systemic antibiotics or the
presence of a central venous catheter during the 3 preced-
ing days and at least two of the preceding risk factors was
able to identify patients with a risk of invasive candidiasis
of at least 10%. However, with a sensitivity of 34% this rule
captured only one third of cases of invasive candidiasis.
The usefulness of a risk-factors-based predictive rule has
been suggested in a medical ICU where antifungals were
empirically prescribed accordingly [73]. Thirty-six (2.6%)
of all patients admitted received antifungals empirically,
allowing a significant decrease of the rate of fungal cathe-
ter-related bloodstream infections from 3.4 to 0.79 epi-
sodes per 1,000 catheter-days. The sensitivity of such
clinical predictive rule was markedly improved (66%) with
a maintained specificity (87%) by taking into account the
presence of Candida colonization at time of its assessment
[74]. This new rule is currently investigated in a rando-
mized, placebo-controlled, pilot study on empirical ther-
apy with caspofungin in high-risk ICU patients (MSG-04
in mixed patients, INTENSE study in surgical patients,
http://www.clinicaltrials.gov).
However, the common characteristics of risk scores
and clinical rules is not their relatively low positive pre-
dictive value for diagnosing invasive candidiasis but
their high negative predictive value for ruling out infec-
tion. This may allow withholding a number of unneces-
sary antifungal treatments in critically ill patients.
Management of invasive candidiasis in critically ill
patients
Rapid initiation of appropriate antifungal therapy has
been shown to reduce mortality in patients with candide-
mia [24,75]. Prophylaxis should strongly be restricted to
very specific subgroups of patients in whom it has been
demonstrated to be useful (Table 3). Preemptive therapy
for colonized patients or those with high-risk scores and
empirical therapy in septic patients not responding to
appropriate antibacterial treatment are possible early
interventions (Figure 2) [28,60].
Practical approach to early diagnosis of invasive
candidiasis in critically ill patients
Although recognized as a strong risk factor, coloniza-
tion, which may occur early after ICU admission, does
not justify the start of empirical antifungal treatment
[76]. Despite promising preliminary results, biomarkers
are currently only available for research purpose.
Accordingly, clinicians should continue to combine risk
factors and the dynamic of colonization to try to identify
Figure 2 Concept of antifungal treatments in critically ill patients.
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early critically ill patients susceptible to benefit from
early empirical antifungal treatment (Figure 3).
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